PepGen announces issuance of patent for PGN-EDODM1

PepGen (PEPG) announced that the United States Patent and Trademark Office has issued the company a new composition of matter patent covering PGN-EDODM1, which leverages PepGen’s proprietary enhanced delivery Oligonucleotide platform, including its unique peptide and linker chemistry. This newly issued composition of matter patent is expected to provide exclusivity for PGN-EDODM1 in the United States into second half of 2042, with the possibility of patent term extension following FDA approval of PGN-EDODM1.